Treatment of Hot Flashes in Peri- and Post-Menopausal Women
Introduction to Treatment Options
- The American College of Obstetricians and Gynecologists recommends hormone replacement therapy (HRT) as the gold standard treatment for hot flashes in peri- and post-menopausal women, reducing hot flashes by 75-90% 1, 2
First-Line Treatment: Hormone Replacement Therapy
- For women without contraindications, the North American Menopause Society recommends transdermal estradiol 50 μg patch, changed twice weekly, as the preferred first-line therapy for women without a uterus (post-hysterectomy) 1, 2
- The American College of Obstetricians and Gynecologists recommends combined estrogen-progestin therapy for women with an intact uterus to prevent endometrial cancer, with micronized progesterone preferred over medroxyprogesterone acetate due to lower breast cancer and VTE risk 1
Non-Hormonal Pharmacologic Options
- The National Comprehensive Cancer Network recommends venlafaxine as the most effective non-hormonal option, reducing hot flashes by approximately 60% 3
- The American College of Obstetricians and Gynecologists recommends gabapentin 900 mg/day as an alternative, especially for women with sleep disturbance, reducing hot flash severity score by 46% vs 15% with placebo 3
Non-Pharmacologic Interventions
- The North American Menopause Society recommends acupuncture as a safe and effective option for managing vasomotor symptoms, with several studies showing equivalence or superiority to venlafaxine or gabapentin in cancer survivors 3
- The American College of Obstetricians and Gynecologists recommends cognitive behavioral therapy (CBT) and clinical hypnosis as useful adjuncts to pharmacologic therapy, reducing hot flashes 3, 1
Contraindications and Precautions
- The American College of Obstetricians and Gynecologists recommends against initiating HRT solely for chronic disease prevention in asymptomatic women, as this increases morbidity and mortality 1
- The North American Menopause Society recommends against prescribing estrogen-alone to women with an intact uterus, as this dramatically increases endometrial cancer risk 1